yingweiwo

KI696 isomer

Cat No.:V32222 Purity: ≥98%
KI696 isomer is a less active isomer of KI696.
KI696 isomer
KI696 isomer Chemical Structure CAS No.: 1799974-69-8
Product category: New2
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
25mg
100mg
500mg
1g
Other Sizes

Other Forms of KI696 isomer:

  • KI-696
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
KI696 isomer is a less active isomer of KI696. KI696 is a high-affinity probe that disrupts the Keap1/NRF2 interaction.
Biological Activity I Assay Protocols (From Reference)
ln Vitro
KI-696 disrupts the KEAP1-NRF2 interaction, leading to NRF2 stabilization, nuclear translocation, and activation of the antioxidant response pathway.
In Normal Human Bronchial Epithelial (NHBE) cells, treatment with KI-696 for 6 hours increased nuclear NRF2 protein accumulation in a concentration-dependent manner [1].
In NHBE cells transfected with NRF2 siRNA, KI-696 (1 µM) upregulated mRNA expression of NRF2-dependent genes NQO1 and GCLM. This upregulation was significantly decreased by NRF2 gene silencing, confirming an NRF2-dependent mechanism [1].
KI-696 (1 µM) induced NQO1 specific enzyme activity by 6-fold over DMSO control in NHBE cells. NRF2 siRNA abolished approximately 88% of this induced activity [1].
In the human lung epithelial cell line BEAS-2B, KI-696 increased NQO1 enzyme activity with an EC50 of 12 nM [1].
In NHBE cells, pre-treatment with KI-696 prevented tert-butyl hydroperoxide (tBHP)-induced depletion of reduced glutathione (GSH) in a concentration-dependent manner and maintained normal cell morphology [1].
In air-liquid interface (ALI) cultures of bronchial epithelial cells derived from COPD patients, KI-696 treatment for 6 hours upregulated mRNA expression of NRF2-dependent genes (NQO1, TXNRD1, GCLM, HO-1) in a concentration-dependent manner, with an EC50 of 22 nM for NQO1 mRNA expression [1].
A fluorescence polarization (FP) assay measuring inhibition of the Kelch domain-NRF2 interaction showed that intermediate compounds during optimization (e.g., Compound 6) had an IC50 of 0.27 µM [1].
Selectivity screening against a panel of 49 in vitro functional assays revealed minor cross-reactivity with OATP1B1 (IC50 = 2.5 µM), BSEP (IC50 = 4.0 µM), and PDE3A (IC50 = 10 µM). No significant cytotoxicity was observed in BEAS-2B cells at concentrations up to 10 µM [1].
ln Vivo
In Han Wistar rats, intravenous (IV) infusion of KI-696 over 6 hours induced dose-dependent increases in the pulmonary expression of NRF2-regulated genes (Nqo1, Ho-1, Txnrd1, Srxn1, Gsta3, Gclc). The average EC50 for gene induction across these six genes was 36.4 ± 3.4 µmol/kg [1].
IV infusion of KI-696 (35 µmol/kg, approximate average EC50 for gene expression) attenuated ozone-induced pulmonary inflammation in rats. It significantly reduced the ozone-induced increases in total cells, neutrophils, and mononuclear cells in bronchoalveolar lavage (BAL) fluid [1].
IV infusion of KI-696 (10, 35, 50 µmol/kg) restored ozone-induced depletion of lung glutathione (GSH) levels in a dose-dependent manner [1].
Enzyme Assay
The inhibition of the KEAP1 Kelch domain-NRF2 interaction was determined using a fluorescence polarization (FP)-based competition assay. The assay was performed in a 384-well microplate. Each well contained a fluorescently labeled NRF2-derived peptide (5’-TAMRA-AFFAQLQLDEETGEFL) at 2 nM and the human KEAP1 Kelch domain (residues 321-609) at 7 nM in assay buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 5 mM MgCl2, 2 mM CHAPS, 1 mM DTT, 0.005% BSA, 1% DMSO). After incubation for 1 hour at room temperature, fluorescence polarization (excitation 485 nm/emission 520 nm) was measured. IC50 values were determined by fitting the data to a four-parameter logistic model [1].
Binding affinity (Kd) was measured by Isothermal Titration Calorimetry (ITC). Experiments were performed at 25°C in a buffer containing 50 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 1 mM TCEP, and 5% DMSO. The compound was titrated into the sample cell containing the human KEAP1 Kelch domain (residues 321-609). Data were analyzed using appropriate software, and heats of dilution from the final injections were subtracted before analysis [1].
Cell Assay
NRF2 Nuclear Translocation: NHBE cells were plated and cultured until confluent. Cells were treated with compounds or DMSO for 6 hours. Cytoplasmic and nuclear fractions were generated using a modified commercial kit protocol. NRF2 protein levels in the nuclear fraction were quantified using a commercial ELISA-based kit. Data were reported as optical density per µg total protein relative to DMSO control [1].
Gene Expression (siRNA): NHBE cells were transfected with non-targeting or NRF2 siRNA for 48 hours. On the second day post-transfection, cells were treated with compounds for approximately 24 hours. Total RNA was isolated, reverse transcribed to cDNA, and quantified by real-time PCR using specific primer/probe sets for target genes (e.g., NQO1, GCLM) and a housekeeping gene (18S rRNA). Fold changes were calculated using the comparative Ct method [1].
NQO1 Enzyme Activity: NHBE cells were transfected with siRNA for 48 hours, then treated with compounds for an additional 48 hours. Cells were lysed, and protein concentration was determined. NQO1 activity in crude lysates was measured kinetically by monitoring the reduction of a substrate coupled to a colorimetric change, with and without a specific NQO1 inhibitor (dicoumarol). Specific activity was calculated by subtracting the inhibitor-treated values, normalizing to total protein, and expressed as µmol/min/mg protein [1].
BEAS-2B NQO1 Activity: BEAS-2B cells were plated in 384-well plates overnight. Compounds were added for 48 hours. Medium was aspirated, and cells were lysed. NQO1 activity in lysates was measured kinetically using an MTT-based assay, monitoring absorbance at 570 nm over time. Product formation rate was plotted against compound concentration to determine EC50 [1].
Glutathione (GSH) Assay: NHBE cells were treated with compounds for 18 hours, followed by exposure to an oxidative stressor (tBHP) or controls for 4 hours. Cells were then assayed for total glutathione content using a commercial fluorescent detection kit according to the manufacturer's protocol. Results were quantified based on a standard curve [1].
COPD Patient Cell Gene Expression: Bronchial epithelial cells from COPD patients were expanded and differentiated under air-liquid interface (ALI) culture conditions for approximately 28 days. Differentiated ALI cultures were treated with compounds for 6 hours. Total RNA was isolated and subjected to real-time PCR analysis for NRF2 target genes using specific primer/probe sets. Fold changes were calculated relative to a housekeeping gene [1].
Animal Protocol
Pharmacokinetics Study: KI-696 was administered to Han Wistar rats in a standard intravenous (IV) and oral (PO) crossover design. Blood samples were collected over 24 hours, and compound concentrations were determined by LC/MS/MS. Pharmacokinetic parameters were calculated from the blood concentration-time data [1].
In Vivo Gene Expression Study: Male Han Wistar rats received a 6-hour IV infusion of KI-696 or vehicle at various doses (targeting total delivered doses of 5, 10, 25, 50 µmol/kg). Immediately after the infusion, lungs were collected, snap-frozen, and later analyzed for mRNA expression of NRF2-regulated genes by real-time PCR [1].
Ozone-Induced Inflammation Model: Han Wistar rats were administered KI-696 or vehicle by IV infusion over 6 hours. Twenty-four hours after the start of infusion, rats were exposed to ozone (1 ppm) or air for 3 hours. Fifteen minutes post-exposure, rats were euthanized. Bronchoalveolar lavage (BAL) was performed to collect inflammatory cells for total and differential cell counts. In a separate study, lungs were collected post-ozone exposure for GSH measurement using a commercial assay kit. Blood samples were also collected during the infusion to determine compound concentrations [1].
ADME/Pharmacokinetics
In Han Wistar rats, KI-696 was cleared relatively quickly after intravenous injection and had a short half-life[1]. The bioavailability (F) of KI-696 in rats after oral administration was low, reported to be 7%[1]. Steady-state plasma concentrations of KI-696 were 407 ± 44 nM, 946 ± 50 nM and 1437 ± 186 nM after 6-hour intravenous infusion at target doses of 10, 35 and 50 µmol/kg, respectively[1].
Toxicity/Toxicokinetics
In the enhanced cross-screening group (eXP) comprising 49 in vitro functional assays, KI-696 showed inhibitory effects on OATP1B1 (IC50 = 2.5 µM), BSEP (IC50 = 4.0 µM), and PDE3A (IC50 = 10 µM). No significant cross-reactivity was observed in other assays [1]. In cell viability assays, no cytotoxicity was observed in BEAS-2B cells at concentrations up to 10 µM [1].
References

[1]. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery. J Med Chem. 2016 Apr 28.

Additional Infomation
KI-696 was discovered using a fragment-based drug discovery (FBDD) approach. X-ray crystallography screening identified three binding “hot spots” in the NRF2 pocket of KEAP1. Optimization from a weakly active fragment (Kd > 1 mM) yielded KI-696 with nanomolar affinity [1].
This compound is a monoacid inhibitor containing only one carboxylic acid group, unlike polyacid peptide ligands. It is not a peptide mimic, but conforms to the three pharmacophores (acid, aroma receptor, sulfonamide) identified in the fragment screening [1].
The main potential therapeutic use of this compound is to treat diseases involving oxidative stress and inflammation, such as chronic obstructive pulmonary disease (COPD). This study confirmed its activity in cell and animal models associated with COPD [1].
KI-696 is a non-covalent direct inhibitor of the KEAP1-NRF2 protein-protein interaction (PPI) and may have a greater selectivity than electrophilic NRF2 activators that covalently modify KEAP1 cysteine[1].
This compound is positioned as a high-quality chemical probe for exploring the therapeutic potential of disrupting the KEAP1-NRF2 interaction[1].
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C28H30N4O6S
Molecular Weight
550.626005649567
Exact Mass
550.188
CAS #
1799974-69-8
Related CAS #
KI696; 1799974-70-1; KI696 isomer; 1799974-69-8
PubChem CID
118169940
Appearance
White to off-white solid powder
LogP
3.5
tPSA
132
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
9
Rotatable Bond Count
7
Heavy Atom Count
39
Complexity
962
Defined Atom Stereocenter Count
2
SMILES
S1(C2C=CC=CC=2O[C@H](C)CN1CC1C(C)=CC=C(C=1)[C@@H](CC(=O)O)C1C=C(C2=C(C=1)N=NN2C)OC)(=O)=O
InChi Key
ZDNGJXBUEQNFBQ-XMSQKQJNSA-N
InChi Code
InChI=1S/C28H30N4O6S/c1-17-9-10-19(22(14-27(33)34)20-12-23-28(25(13-20)37-4)31(3)30-29-23)11-21(17)16-32-15-18(2)38-24-7-5-6-8-26(24)39(32,35)36/h5-13,18,22H,14-16H2,1-4H3,(H,33,34)/t18-,22-/m1/s1
Chemical Name
(3R)-3-(7-methoxy-1-methylbenzotriazol-5-yl)-3-[4-methyl-3-[[(4R)-4-methyl-1,1-dioxo-3,4-dihydro-5,1λ6,2-benzoxathiazepin-2-yl]methyl]phenyl]propanoic acid
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO : ~125 mg/mL (~227.01 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.8161 mL 9.0805 mL 18.1610 mL
5 mM 0.3632 mL 1.8161 mL 3.6322 mL
10 mM 0.1816 mL 0.9081 mL 1.8161 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration: mg/mL;

Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Contact Us